Frontline therapy for newly diagnosed patients with multiple myeloma

Since the introduction of an alkylator to the treatment of multiple myeloma (MM), new effective agents have been developed, such as immunomodulatory drugs including thalidomide, lenalidomide, and pomalidomide; proteasome inhibitors including bortezomib, carfilzomib, and ixazomib; monoclonal antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Sung-Hoon, Jo, Jae-Cheol, Song, Ga-Young, Ahn, Seo-Yeon, Yang, Deok-Hwan, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386893/
https://www.ncbi.nlm.nih.gov/pubmed/32719175
http://dx.doi.org/10.5045/br.2020.S007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386893/
https://www.ncbi.nlm.nih.gov/pubmed/32719175
http://dx.doi.org/10.5045/br.2020.S007

Ejemplares similares